December 02, 2009

BioSyntech Announces Management Changes

LAVAL, Quebec – December 2, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that Ms. Antoinette Lizzi, Chief Financial Officer, will leave the Company effective December 2, 2009 and Ms. Catherine Auld, CA, will join the Company as Chief Financial Officer.   More

November 16, 2009

BioSyntech Announces Second Quarter Fiscal 2010 Financial Results

LAVAL, Quebec - November 16, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the second quarter of fiscal 2010, ended September 30, 2009.   More

October 16, 2009

BioSyntech Announces Closing of $3.1 Million Rights Offering

LAVAL, Quebec – October 16, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, announces the successful closing of its previously announced offering of rights to purchase 310,000 units,   More

September 09, 2009

BioSyntech Presents Bst-Cargel® Cartilage Repair Trial Design at the 2009 World Congress on Osteoarthritis in Montreal

LAVAL, Quebec – September 9, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced it will present a poster entitled “Challenges in Designing Randomized Clinical Trials for Cartilage Repair: The BST-CarGel® Experience”   More

August 31, 2009

BioSyntech Announces Filing of Final Prospectus for $3.1 Million Rights Offering

LAVAL, Quebec - August 31, 2009 - BioSyntech, Inc. (“BioSyntech”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has filed a final short form prospectus in respect of the distribution to its existing shareholders of rights exercisable to purchase 310,000 units, each comprised of $10 principal amount of subordinated secured convertible debentures and 91 common share purchase warrants, at a price of $10 per unit, representing gross aggregate proceeds of up to $3,100,000 to BioSyntech.   More

August 24, 2009

BioSyntech Appoints Chairman and Additional Director to Its Board

LAVAL, Quebec - August 24, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced it has appointed two additional members to its Board of Directors, Mr. André Archimbaud and Ms. Jeanne Bertonis, Chief Executive Officer for BioSyntech. Mr. Archimbaud will serve as Chairman of the Board.   More

August 24, 2009

BioSyntech Announces Completion of $1.4 Million Private Placement and Launch of $3.1 Million Rights Offering

LAVAL, Quebec - August 24, 2009 - BioSyntech, Inc. (“BioSyntech”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has completed its previously announced private placement of an aggregate of 140,000 units of BioSyntech, each comprised of $10 principal amount of subordinated secured convertible debentures and 91 common share purchase warrants, to Highland Crusader Offshore Partners, L.P. (“Highland”), ProQuest Investments III, L.P. (“ProQuest”), Fonds de Solidarité des travailleurs du Québec (F.T.Q.) (“FSTQ”), A. M. Papp   More

August 14, 2009

BioSyntech Appoints Chief Executive Officer

LAVAL, Quebec - August 14, 2009 - BioSyntech, Inc. (TSX: BSY) a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has appointed Ms. Jeanne Bertonis, MBA, M.Sc., to the role of Chief Executive Officer. The Company previously announced that Ms. Bertonis was retained by BioSyntech as a consultant to assist the Company with its research and development, regulatory, strategic planning and business development strategies.   More

August 14, 2009

BioSyntech Announces First Quarter Fiscal 2010 Financial Results

LAVAL, Quebec - August 14, 2009 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the first quarter of fiscal 2010, ended June 30, 2009.   More

August 14, 2009

BioSyntech Announces $4.5 Million Financing

LAVAL, Québec — August 14, 2009 — BioSyntech, Inc. (“BioSyntech”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has entered into an agreement with ProQuest Investments III, L.P. (“ProQuest”), Fonds de Solidarité des travailleurs du Québec (F.T.Q.) (“FSTQ”), Highland Crusader Offshore Partners, L.P. (“Highland”) and A. M. Pappas Life Science Ventures III, LP and PV III CEO Fund, LP (collectively, “Pappas” and, together with ProQuest, FSTQ and Highland, the “Investors”) pursuant to which:   More

July 24, 2009

BioSyntech Appoints Chief Financial Officer

LAVAL, Quebec — July 24, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has appointed Ms. Antoinette Lizzi, CMA, to the position of Chief Financial Officer.   More

July 21, 2009

BioSyntech Appoints PricewaterhouseCoopers as Financial Advisor

LAVAL, Quebec — July 21, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has retained the services of PricewaterhouseCoopers LLP to act as its financial advisor with respect to the Company’s formal review of strategic alternatives including, but not limited to, a commercial partnership involving its cartilage repair device BST-CarGel® or a corporate sale of the Company. There can be no assurance that this strategic review will result in any specific transactions and no timetable has been set fo   More

July 15, 2009

BioSyntech Announces Management Changes

LAVAL, Quebec — July 15, 2009 — BioSyntech, Inc. (TSX: BSY) announced today that it has retained the services of Ms. Jeanne Bertonis to assist the Company with its research and development, regulatory, strategic planning and business development strategies. Ms. Bertonis has 25 years of experience in the drug, device and biomaterials industries. She held the positions of Chief Business Officer and Vice President, Corporate Development for Angiotech Pharmaceuticals from 2000-2006,   More

July 06, 2009

BioSyntech Announces Appointment of New Board Member

LAVAL, Quebec — July 6, 2009 — BioSyntech, Inc. (TSX: BSY) (the Company) announced today the appointment of Mr. Lee E. Brown as member of the Board of Directors. Mr. Brown was designated by Highland Capital Management to replace Mr. Nick Losey on the Company’s Board. Under the terms of an underwriting agreement signed in connection with the July 2008 debenture financing, Highland Capital Management has the right to nominate one member to the Board of the Company.   More

June 29, 2009

BioSyntech Announces Year End and Fourth Quarter Fiscal 2009 Financial Results and Management Changes

LAVAL, Quebec — June 29, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the fiscal year, ending March 31, 2009.   More

June 17, 2009

BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel® Cartilage Repair Device

LAVAL, Quebec — June 17, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced statistically significant results from an analysis of patients who completed their 12 month follow-up in the BST-CarGel® randomized clinical trial.   More

June 11, 2009

BioSyntech Gives Notice to Debentureholders and Announces Resignation of Board Member

LAVAL, Quebec — June 11, 2009 — BioSyntech, Inc. (TSX: BSY) (the Company) gave notice to its debentureholders that it exercised its right to make the interest payment of $745,800 due on June 30, 2009 by issuing common shares. The number of common shares to be issued on June 30, 2009 will be equal to the amount of the interests, divided by 95% of the volume weighted average trading price per common share for the five trading days immediately preceding.   More

May 01, 2009

BioSyntech Announces Resignation of Board Member and Appointment of New Board Member

LAVAL, Quebec — May 1, 2009 — BioSyntech, Inc. (TSX: BSY) (the Company) announced today that Mr. Winston Black has tendered his resignation as member of the Board. This resignation is subsequent to Mr. Black’s resignation from Highland Capital Management. Under the terms of an underwriting agreement signed in connection with the July 2008 debenture financing, Highland Capital Management has the right to nominate one member to the Board of the Company.   More

March 30, 2009

BioSyntech Forms Special Committee

LAVAL, Quebec — March 30th, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that its Board of Directors has formed a Special Committee to review the strategic alternatives of the Company, including partnering activities with the orthopaedic industry,   More

March 12, 2009

BioSyntech to Conduct Substantial Interim Analysis on Half of Enrolled Patients from BST-CarGel® Pivotal Trial

LAVAL, Quebec — March 12, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it will conduct an interim analysis of the available clinical data from 40 subjects who have completed their 12 month follow-up in the 80 subject trial for its cartilage repair device, BST-CarGel®. The Company expects to have the results from this analysis available in the second quarter of 2009.   More

February 20, 2009

BioSyntech Appoints Chief Financial Officer

LAVAL, Quebec — February 20, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has appointed Mr. Louis Lemire, CA, to the to the position of Chief Financial Officer. Mr. Lemire joined the Company as a consultant in October 2008 and was appointed Vice President, Finance in December 2008.   More

February 13, 2009

BioSyntech Announces Third Quarter Fiscal 2009 Financial Results

LAVAL, QC, Feb. 13 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the third quarter of fiscal 2009, ended December 31, 2008.   More

February 02, 2009

BioSyntech achieves enrolment goal for pivotal trial of BST-CARGEL®, its cartilage repair device

LAVAL, Quebec — February 2, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has completed enrolment for the Canadian-European pivotal trial of its cartilage repair device, BST-CarGel®. The Company achieved its planned objective of enrolling 80 patients into the randomized trial.   More

January 26, 2009

BioSyntech Announces Changes to Board of Directors

LAVAL, QC, Jan. 26 - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that Dr. Amine Selmani has resigned from its Board of Directors effective January 23, 2009. Dr. Selmani is the founder of BioSyntech and was its Chief Executive Officer from 1995 to 2004 and subsequently Chairman of the Board of Directors until 2006.   More

January 13, 2009

BioSyntech to Conclude Enrolment for Pivotal BST-CarGel® Trial in February 2009

LAVAL, Quebec — January 12, 2009 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it will conclude enrolment next month for the Canadian-European pivotal trial of its cartilage repair device, BST-CarGel®. To date, the Company has enrolled more than 70 subjects and participating clinical sites will be permitted to enrol additional subjects until February 10th, 2009.   More

December 17, 2008

BioSyntech Announces Management Change

LAVAL, Quebec — December 16, 2008 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that Mr. Francois Michaud has tendered his resignation as CFO, effective February 16, 2009.   More

November 13, 2008

BioSyntech Announces Second Quarter 2009 Financial Results

LAVAL, Quebec — November 13, 2008 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for the second quarter of fiscal 2009, ended September 30, 2008.   More

October 17, 2008

BioSyntech Announces Resignation of CEO and Appointment of New Board Member

LAVAL, Quebec — October 17, 2008 — BioSyntech, Inc. (TSX: BSY) (the Company) announced today that Mr. Claude LeDuc has tendered his resignation, effective December 31, 2008, as CEO of the Company to pursue other interests. He also resigned immediately as a member of the Board.   More

August 12, 2008

BioSyntech Announces First Quarter 2009 Financial Results

LAVAL, Quebec — August 12, 2008 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for first quarter of its fiscal year 2009, ended June 30, 2008.   More

July 22, 2008

BioSyntech Appoints New Board Members

Laval, Québec, July 22, 2008 — BioSyntech, Inc. (the “Company”) (TSX:BSY) is pleased to announce that Mr. Michel Lagueux, Dr. Karen Hong, Mr. Eric W. Linsley and Mr. Winston Black have been appointed to the Board of Directors, effective immediately.   More

July 18, 2008

BioSyntech Announces Exercise of Over-Allotment Option

Laval, Québec, July 18, 2008 — BioSyntech, Inc. (the “Company”) (TSX:BSY) is pleased to announce that as part of the exercise of the over-allotment option in its previously announced bought deal,   More

July 15, 2008

BioSyntech Completes $11 Million Bought Deal

Laval, Québec, July 15, 2008 — BioSyntech, Inc. (the “Corporation”) (TSX:BSY) is pleased to announce that it has closed its previously announced bought deal.   More

July 08, 2008

BioSyntech, Inc. Announces Filing of Final Prospectus and Obtention of Conditional Listing Approval from the TSX and Provides an Update on Its Convertible Debenture Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.   More

June 27, 2008

BioSyntech Announces 2008 Year-End Financial Results and the Adoption of a New Strategic Plan

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.   More

June 20, 2008

BioSyntech Announces Increase to Bought Deal

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.   More

June 18, 2008

BioSyntech Responds To TSX Listing Review

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.   More

June 16, 2008

BioSyntech Announces $10 Million Bought Deal Financing

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.   More

April 24, 2008

BioSyntech Announces BST-DermOnTM Abstract Selected For Poster Presentation at the 2008 World Union of Wound Healing Societies Congress

LAVAL, Quebec, April 24, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced that its abstract summarizing the safety and effectiveness of BST-DermOn™ in promoting the healing of various types of chronic wounds that have failed previous treatments,   More

April 07, 2008

BioSyntech Receives ISO13485:2003 Certification For Its Quality Management System

LAVAL, Quebec, April 07, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced that it has achieved international certification under the stringent and globally recognized ISO 13485:2003   More

March 17, 2008

BioSyntech Announces Positive Preliminary Interim Data for BST-CarGel® Clinical Trial

LAVAL, Quebec, March 17, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced it has received positive preliminary results from a prospectively planned six-month interim analysis of its Canadian-European pivotal clinical trial for BST-CarGel®.   More

March 04, 2008

BioSyntech Announces Five Poster Presentations at 54th Annual Meeting of the Orthopaedic Research Society

LAVAL, Quebec — March 4, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that five abstracts have been selected for presentation as posters at the 54th Annual Meeting of the Orthopaedic Research Society (“ORS”) held from March 2-5, 2008 in San Francisco, California.   More

February 14, 2008

BioSyntech announces third quarter 2008 financial results

LAVAL, Quebec — February 13, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial results for the three and nine-month periods ended December 31, 2007.   More

November 27, 2007

BioSyntech Awarded 2007 Innovation Award from ADRIQ

LAVAL, Quebec — November 27, 2007 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced it has been awarded the 2007 Innovation Award in the “Partnership” category by the Association de la Recherche Industrielle du Quebec (ADRIQ) for its successful partnership with the École Polytechnique de Montréal (École Polytechnique).   More

November 12, 2007

Biosyntech Announces Second Quarter 2008 Financial Results

LAVAL, Quebec — November 12, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial results for the three and six-month periods ended September 30, 2007.   More

August 13, 2007

BioSyntech announces first quarter 2008 financial results

LAVAL, Quebec, Canada — August 13, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced financial results for the first quarter ended June 30, 2007.   More

July 11, 2007

Biosyntech appoints new vice president, regulatory affairs and quality

LAVAL, Quebec, Canada — July 11, 2007 —- BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX: BSY) today announced that Mrs. Flor del Pilar Arana has been appointed Vice President, Regulatory Affairs and Quality.   More

June 29, 2007

BioSyntech announces fourth quarter and 2007 year-end financial results

LAVAL, Quebec, Canada — June 29, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY) today announced financial results for the fourth quarter and fiscal year ended March 31, 2007.   More

June 14, 2007

BioSyntech reaches significant BST-CarGel® clinical milestone

LAVAL, Quebec, Canada — June 14, 2007 — BioSyntech Inc. (TSX: BSY) announced today that it has completed the enrolment of a 20 patient subset of its ongoing Canadian-European BST-CarGel® pivotal trial. The data collected from these patients will be submitted to the U.S. Food and Drug Administration as a pilot study in support of an Investigational Device Exemption (IDE) for a US pivotal trial.   More

April 02, 2007

BioSyntech announces refinancing of loan

LAVAL, Québec, Canada —April 2, 2007 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX: BSY) today announced that it has entered into a formal agreement with the Business Development Bank of Canada (the “BDC”), to refinance part of their loan of $2,500,000 by way of conventional mortgage.   More

February 14, 2007

BioSyntech reports its third quarter results

LAVAL, Québec, Canada — February 14, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY) today reported its results for its third quarter and nine-month period ended December 31, 2006.   More

February 08, 2007

BioSyntech announces start of patient recruitment into BST-DermOnTM pivotal clinical trial

LAVAL, Quebec, Canada — February 8, 2007 — BioSyntech Inc. (TSX: BSY) announced today the start of recruitment into its Canadian pivotal clinical trial for BST-DermOnTM, a medical device designed to repair chronic wounds and based on the natural polysaccharide chitosan. Dr. Gary Sibbald, an internationally recognized leader in the field of dermatology and wound repair, is the Principal Investigator for this trial.   More

December 04, 2006

Monday, December 4 - BioSyntech, Inc. Opens the Markets

Claude LeDuc, CEO of BioSyntech, Inc., opened the markets today. BioSyntech is a biotechnology company specializing in the discovery, development, and manufacturing of innovative, cost-effective, and physician-friendly therapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech trades on TSX under the stock symbol BSY.    More

November 29, 2006

BioSyntech reports second quarter results

LAVAL, Québec, Canada — November 29, 2006 — BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX: BSY) today reported its results for the second quarter and six-month period ended September 30, 2006.   More

November 20, 2006

BioSyntech signs scientific collaboration agreement with Nicholas Piramal

Laval, Quebec, Canada — November 20, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX:BSY) is pleased to announce the signing of a scientific collaboration between the Company and their biopharmaceutical partner Nicholas Piramal.   More

October 30, 2006

BioSyntech shares begins trading on the TSX today

LAVAL, Québec, Canada — October 30, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange ("TSX") at the open of trading today, Monday October 30, 2006 under the symbol “BSY”.   More

October 11, 2006

BioSyntech Receives Notice of Allowance from the US Patent and Trademark Office on Key BST-CarGel® Patent

LAVAL, Québec, Canada — October 11, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that on September 20, 2006, it received a Notice of Allowance from the US Patent and Trademark Office on their key BST-CarGel® patent entitled, “Composition and method for the repair and regeneration of cartilage and other tissues”. BST CarGel®, the Company's lead product,   More

September 29, 2006

BioSyntech announces conditional approval for listing on the Toronto Stock Exchange

LAVAL, Québec, Canada — September 29, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce that its application to graduate to the Toronto Stock Exchange has been approved, subject only to the filing of final documentation.   More

September 25, 2006

Annual meeting of stockholders of BioSyntech, Inc.

LAVAL, QUEBEC, September 25, 2006 – Mr. Joseph Benarrosh, Chairman of the Board announces the Annual Meeting of Stockholders of BioSyntech, Inc.   More

August 25, 2006

BioSyntech reports first quarter results

LAVAL, Québec, Canada — August 25, 2006 — BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX-V: BSY) today reported its results for the first quarter ended June 30, 2006.   More

August 24, 2006

BioSyntech receives approval for Canadian BST-DermOn® pivotal clinical trial

LAVAL, Quebec, Canada — August 24, 2006 — BioSyntech Inc. (TSX-V: BSY) announced today that it has received approval from Health Canada, Therapeutic Products Directorate, Medical Devices Bureau, to begin enrolling subjects in its pivotal clinical trial for BST-DermOn®, a medical device designed to repair chronic wounds.   More

August 08, 2006

BioSyntech strengthens management team with key appointments. Company names François Michaud as chief financial officer and Richard Lacombe as vice-president clinical affairs

LAVAL, Québec, Canada — August 8, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce the appointments of Mr. François Michaud C.A., C.M.A., as Chief Financial Officer and Mr. Richard Lacombe Ph.D., M.B.A., as Vice-President Clinical Affairs of the Company.   More

July 28, 2006

BioSyntech reports major progress in fiscal 2006 Strengthens balance sheet with $28 million financing Enhances board with additional members

LAVAL, Québec, Canada — July 28, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today reported its results for the fiscal year ended March 31, 2006.   More

June 13, 2006

BioSyntech strengthens board with new member

LAVAL, Québec, Canada — June 13, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today announced the appointment of Dr. Joyce Tsang to its Board of Directors. Dr. Tsang is the representative for ProQuest Investments, which invested in the Company’s recent financing.   More

May 25, 2006

BioSyntech appoints new board member

LAVAL, Québec, Canada — May 25, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today announced the appointment of Rudy Huber to its board of directors. Mr. Huber is the representative for an institution that invested in the Company’s recent financing.   More

May 10, 2006

BioSyntech grants stock options

LAVAL, Quebec, Canada – May 9, 2006 – In accordance with its continuous disclosure obligations, BioSyntech, Inc. (TSX-V: BSY) announces the grant of options to acquire 50,000 common shares of its capital stock at a price of $0.49 per share for a period of five years to a Board Director.   More

May 03, 2006

BioSyntech closes its private placement for a total of $21 Million with a $3 Million third and final tranche

LAVAL, Quebec, Canada – May 3rd, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today the closing of the third tranche of its previously-announced financing. This final tranche involved the issuance of 7,125,000 Units at $0.42 per Unit for a total of $2,996,700. This brings the total financing to $21 million for the issuance of 50,000,000 Units. Each Unit consisted of one common share and half a warrant. Each full warrant entitles the holder to purchase one share at $0.65 prior to March 31, 2009.   More

April 18, 2006

BioSyntech closes $8 Million second tranche of its private placement and increases total offering to $21,7 Million

LAVAL, Quebec, Canada – April 17, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that it has increased the size of its previously announced private placement to $21,700,000, representing an aggregate of 51,666,666 units, at a price of $0.42 per unit, to accommodate the subscription of two strategic investors.   More

March 31, 2006

BIOSYNTECH, INC. ANNOUNCES FIRST CLOSING OF ITS PRIVATE PLACEMENT FOR AN AMOUNT OF $10 MILLION

LAVAL, Quebec, Canada – March 31, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today a first closing of its private placement involving the issuance of 23,810,000 units at a price of $0.42 per unit for gross proceeds of $10,000,200. Each unit consists of one common share of the Company and one half of one warrant. Each warrant entitles the holder to purchase, for a period of three years, one common share at a price of $0.65 per share.   More

March 20, 2006

BioSyntech Inc. announces new closing date for its private placement, continuation under the Canada Business Corporations Act and appointment of new chairman

LAVAL, Quebec, Canada – March 20, 2006 – BioSyntech Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today the appointment of Joseph Benarrosh as Chairman of its board of directors, following the resignation of Amine Selmani, who remains as a board member. Mr. Benarrosh has been a board member of the Company since 2004.   More

February 28, 2006

BioSyntech Inc. announces proposed private placement

LAVAL, Quebec, Canada – February 28, 2006 – BioSyntech Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that it has retained the services of Desjardins Securities Inc. as lead agent and Dundee Securities Corporation (together, the “Agents”) for a private placement of 23,810,000 units of the Company at a price of $0.42 per unit, for gross proceeds of $10,000,200.   More

February 24, 2006

BioSyntech reports its third quarter results

LAVAL, Québec, Canada — February 24, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today reported its results for its third quarter and nine-month period ended December 31, 2005. Highlights and subsequent events:   More

February 16, 2006

BioSyntech announces extension of BDC loan

LAVAL, Quebec, Canada — February 16, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX-V: BSY) today announced that it has negotiated the extension until February 15, 2009 of the $2,500,000 loan obtained in 2002 from the Business Development Bank of Canada (the “BDC”), on the same terms and conditions. All outstanding interest due on the initial loan, which had been capitalized since disbursement, was paid.   More

February 09, 2006

BioSyntech closes transaction with Kuhnil Pharma Co. LTD

LAVAL, Quebec, Canada — February 9, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today announced the closing of the transaction with Kuhnil Pharma Co. Ltd (“Kuhnil”), one of Korea's leading pharmaceutical companies, pursuant to which Kuhnil purchased 1,500,000 common shares of the Company at a price of $0.80 per share, for total proceeds of $1.2 million.   More

January 09, 2006

BioSyntech's BST-CarGel subject of prestigious publication

LAVAL, Québec, Canada — January 9, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX-V: BSY) announced today that BST-CarGel is the subject of a study published in The Journal of Bone and Joint Surgery (JBJS, American Volume). The paper, entitled “Chitosan-Glycerol Phosphate/Blood Implants Improve Hyaline Cartilage Repair in Ovine Microfracture Defects”   More

December 29, 2005

BioSyntech grants stock options

LAVAL, Québec, Canada — December 23, 2005 — In accordance with its continuous disclosure obligations, BioSyntech, Inc. (TSX-V: BSY) announces the grant of options to acquire 15,000 common shares of its capital stock at a price of $0.69 per share for a period of five years to each of its four independent directors, namely:   More

November 28, 2005

Letter to Shareholders

Dear Shareholder, In the second quarter, we made considerable progress on our strategic plan for fiscal 2006, both at the corporate and at the scientific level. This success can be summed up in the following four initiatives:    More

November 28, 2005

BioSyntech reports its second quarter results

LAVAL, Québec, Canada — November 28, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today reported its results for its second quarter ended September 30, 2005   More

November 16, 2005

BioSyntech receives approval for Canadian BST-CarGel® pivotal clinical trial

LAVAL, Quebec, Canada — November 16, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) announced today that it has received approval from Health Canada, Therapeutic Products Directorate, Medical Devices Bureau, to begin its pivotal clinical trial for BST-CarGel®.   More

October 18, 2005

BioSyntech signs agreement with one of Korea's leading pharma companies

LAVAL, Quebec, Canada — October 18, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today announced the signing of a letter of agreement with Kuhnil Pharma Co. Ltd (“Kuhnil”), one of Korea's leading pharmaceutical companies, pursuant to which Kuhnil will purchase 1,500,000 common shares of the Company at a price of $0.80 per share, for total proceeds of $1.2 million.   More

September 22, 2005

BioSyntech updates shareholders at the Annual General Meeting

LAVAL, Quebec, Canada — September 21, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) was pleased to greet and update its shareholders at the Company’s Annual General Meeting, held in Montreal today.   More

September 20, 2005

BioSyntech retains leading investor relations firm

LAVAL, Quebec, Canada — September 20, 2005 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today announced that it has retained the Equicom Group Inc. (“Equicom”) to provide the Company with strategic investor relations and financial communications services.   More

September 06, 2005

BioSyntech announces closing of private placement

LAVAL, Quebec, Canada — (BUSINESS WIRE) — September 6, 2005 — Further to its press release of August 24, 2005, BioSyntech, Inc. (TSX Venture: “BSY”) is pleased to announce the closing of the private placement of 7,500,000 common shares at a price of $0.80 per share by Nicholas Piramal India Limited (“NPIL”).   More

August 24, 2005

Nicholas Piramal India Limited and BioSyntech, Inc. Announce signing of formal agreements

LAVAL, Quebec, Canada and Mumbai, India — (BUSINESS WIRE) — August 24, 2005 — Further to its press release of July 7, 2005, BioSyntech, Inc. (TSX Venture: “BSY”) is pleased to announce that the final agreements with respect to the private placement of 7,500,000 common shares of the company at a price of CDN$0.80 per share by Nicholas Piramal India Limited (“NPIL”) have been signed today. Closing will occur as soon as regulatory approvals has been obtained in Canada and India.   More

July 07, 2005

BioSyntech, Inc. and Nicholas Piramal India Limited Announce Letter of Intent

BioSyntech, Inc. (TSX VENTURE:BSY) has signed a letter of intent with Nicholas Piramal India Limited ("NPIL"), one of India's leading pharmaceutical companies, pursuant to which NPIL will subscribe to 7,500,000 common shares of the company at a price of C$0.80 per share. NPIL's post-issue shareholding will be approximately 17% of issued shares.   More

May 10, 2005

BioSyntech files application for investigational testing authorization (ITA) for Canadian multi-center clinical trial for BST-CarGel®.

BioSyntech, Inc (TSX Venture Exchange "BSY.V") is seeking approval from Health Canada to begin a pivotal clinical trial for its cartilage repair device, BST-CarGel®.   More

March 07, 2005

BioSyntech signs agreement with MedQualis as BST-DermOnTM and BST-InPodTM clinical trial CRO, and with the LIO (Imaging and Orthopaedics Research Laboratory) for BST-InPodTM biomechanical outcome assessment

BIOSYNTECH (TSX Venture Exchange 'BSY') is pleased to announce the appointment of MedQualis, a contract research organization (CRO) to support BioSyntech in their upcoming BST-DermOn™ and BST-InPod™ Canadian clinical trials.   More

January 24, 2005

BioSyntech enhances management team as product candidates move towards commercialization

BIOSYNTECH (TSX Venture Exchange: BSY) announces the appointment of three new members to its management team as the Company gears up for the commercialization in Canada and Europe of BST-CarGel™ in 2006 and continues development of its other product candidates. Mr. Gilles Chaumillon, PhD, MBA, is appointed Senior Director, Project Management, with overall responsibility for all projects while Ms. Geneviève Hamel becomes Director, Project Management with responsibilities that include a particular focus on BST-CarGel™ . Together, they have the responsibility to bring to term our ...   More

December 21, 2004

BioSyntech receives first tranche of $1 million from La Financière du Québec

BIOSYNTECH (TSX Venture Exchange: BSY) announces that La Financière du Québec has paid out the first tranche of $1million of the $2.5-million venture loan that it granted the Company on March 15, 2004. In accordance with the terms of this loan, La Financière du Québec has been granted an option, for a five-year period, to acquire 300,000 shares of the Company at $1.25 per share.   More

November 10, 2004

Dr Michael Buschmann to receive the Innovator Prize for 2004 from ADRIQ

BIOSYNTECH (TSX Venture Exchange: BSY) is pleased to announce that Michael D. Buschmann, Professor of Chemical Engineering and Biomedical Engineering at Ecole Polytechnique and Vice-President, Discovery at BioSyntech will receive the Innovator Prize for 2004 from the Association of Industrial Research of Quebec (ADRIQ) at the 14th ADRIQ Gala in Montreal on November 25.   More

September 23, 2004

Annual General Meeting of Shareholders: BioSyntech focuses on maximizing potential revenues

At its annual general meeting of shareholders, BioSyntech (TSX Venture Exchange: BSY) explained its strategy for maximizing potential revenues from its lead products, indicated its intention of forming a strategic distribution alliance with a global partner and outlined important achievements for 2004 including the completion of $3.8 million in financing in March 2004.   More

September 01, 2004

BioSyntech signs CATO Research as BST-CarGel® clinical trial CRO

BIOSYNTECH (TSX Venture Exchange ‘BSY’) is pleased to announce the signing of a Master Service Agreement with Cato Research Ltd., a contract research organization (CRO) that will support BioSyntech in their upcoming BST-CarGel® clinical trials.   More

August 30, 2004

BioSyntech quarterly results and highlights

BIOSYNTECH (TSX Venture Exchange: BSY) released today its first quarter financial results for the period ending June 30, 2004, including recent operating highlights. The documents can be consulted at www.sedar.com or at www.biosyntech.com   More

July 12, 2004

Message from Mr. Claude Leduc, CEO of BioSyntech

At a presentation to shareholders and analysts held in Montreal today, Mr Claude Leduc, President and CEO of BioSyntech, Inc, introduced the company's new strategic plan and made the following statements:   More

June 23, 2004

BioSyntech, Inc.: Delisting from OTCBB

BioSyntech, Inc (TSX Venture Exchange "BSY.S" - OTCBB:"BSYI") announces that it has terminated the registration of its common shares from the US equity markets effective on June23, 2004.   More